Who are Control Vaccine Typbar TCV®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Typhim Vi (Sanofi Pasteur MSD), Vi-TT, Prevnar 20, PCV10 full dose, Menveo®/Menactra®, Streptococcus pneumoniae serotype 3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/control-vaccine-typbar-tcv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Control Vaccine Typbar TCV® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Control Vaccine Typbar TCV® (Control Vaccine Typbar TCV®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Salmonella typhi Vi polysaccharide antigen Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Control Vaccine Typbar TCV® (Control Vaccine Typbar TCV®) — International Vaccine Institute. Typbar TCV is a conjugate vaccine that stimulates immune response against Salmonella typhi by presenting purified polysaccharide antigens conjugated to a carrier protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Control Vaccine Typbar TCV® TARGET	Control Vaccine Typbar TCV®	International Vaccine Institute	phase 3	Conjugate vaccine	Salmonella typhi Vi polysaccharide antigen
Typhim Vi (Sanofi Pasteur MSD)	Typhim Vi (Sanofi Pasteur MSD)	Universitaire Ziekenhuizen KU Leuven	marketed	Inactivated bacterial vaccine	Salmonella typhi Vi polysaccharide antigen
Vi-TT	Vi-TT	International Vaccine Institute	marketed	Typhoid conjugate vaccine	Salmonella typhi Vi polysaccharide antigen
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
PCV10 full dose	PCV10 full dose	Epicentre	marketed	Pneumococcal conjugate vaccine
Menveo®/Menactra®	Menveo®/Menactra®	Massachusetts General Hospital	marketed	Conjugate vaccine	Neisseria meningitidis serogroups A, C, W, and Y
Streptococcus pneumoniae serotype 3	Streptococcus pneumoniae serotype 3	University of Oxford	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae serotype 3 capsular polysaccharide

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Conjugate vaccine class)

GlaxoSmithKline · 26 drugs in this class
Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
CanSino Biologics Inc. · 3 drugs in this class
MCM Vaccines B.V. · 3 drugs in this class
Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
PT Bio Farma · 2 drugs in this class
LG Life Sciences · 2 drugs in this class
Walvax Biotechnology Co., Ltd. · 2 drugs in this class
Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Control Vaccine Typbar TCV® — Competitive Intelligence Brief. https://druglandscape.com/ci/control-vaccine-typbar-tcv. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab